RICHMOND, Va.– Today Phlow™ Corp. released the following statement on the introduction of H.R. 5388, the Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act of 2021 in the United States House of Representatives.
Phlow appreciates the bipartisan leadership and forward-thinking of the sponsors: Rep. Abigail Spanberger (D-VA) and Rep. David B. McKinley (R-WV). The House bill builds upon work already begun as a bicameral, bipartisan effort as companion legislation has previously been introduced in the Senate by Senators Sherrod Brown (D-OH) and Bill Cassidy, MD (R-LA). When enacted, this legislation will ensure a reliable supply of essential medicines for all Americans. Essential medicines, as published by the U.S. Food and Drug Administration last year, are the priority medications necessary to sustain the health of the American population or that are medically necessary to have available at all times. The intent of the “PREPARE” Act aligns with Phlow’s commitment to build a stable, reliable domestic supply chain and stockpile for essential medicines, including key ingredients.
This continued collaboration between Democrats and Republicans on both sides of the Hill signals that the U. S. Government recognizes the importance of enhancing domestic manufacturing, as well as providing diversity in the essential medicine supply chain. Phlow has long supported the need for a national strategic active pharmaceutical ingredient reserve, as well as other production facilities to ensure all Americans have an uninterrupted supply of affordable essential medicines, including medical countermeasures and critical pharmaceutical inputs. Enactment of this legislation will be a critical step towards ending essential medicine shortages.
Phlow™ Corp. is a trailblazing, essential medicines impact company that is reimagining essential medicines from start to finish through the use of flow chemistry and other advanced development and manufacturing processes. Everything Phlow does is designed to promote access to affordable, high-quality essential medicines for all Americans. Phlow is working to provide a solution to the broken essential medicines supply chain by establishing a resilient end-to-end solution that is U. S. -based, comprehensive, and fully integrated. With the support of an industry leading team, experienced strategic partners, and established relationships at the policy, regulatory, and federal levels, Phlow will manufacture active pharmaceutical ingredients and finished pharmaceutical products domestically for essential medicines critical to the nation’s healthcare. Through the use of continuous-flow processes and other green chemistry approaches, Phlow is able to reduce costs and waste, improve quality and yield, and offer a more environmentally friendly alternative to batch manufacturing.